Clinical Trials Browser

Meningeal Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms, Meningeal Carcinomatosis

NCT07092202 2025-07-29

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Phase 4 Recruiting

40 enrolled

CNS

Meningeal Carcinomatosis

NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Phase 2 Terminated

10 enrolled

CNS

Meningeal Carcinomatosis

NCT04460937 2025-07-08

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase 1 Active not recruiting

4 enrolled 9 charts

CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

NCT04420598 2025-06-24

DEBBRAH

Phase 2 Completed

41 enrolled 32 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT00527410 2025-05-30

LMD

Phase 1 Terminated

9 enrolled

CNS

Meningeal Carcinomatosis

NCT06984523 2025-05-25

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

Phase NA Not yet recruiting

20 enrolled

CNS

Meningeal Carcinomatosis

NCT06762080 2025-05-20

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

36 enrolled

CNS

Meningeal Carcinomatosis

NCT06809517 2025-05-20

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

34 enrolled

CNS

Meningeal Carcinomatosis

NCT06809530 2025-05-18

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

34 enrolled

CNS

Meningeal Carcinomatosis

NCT06971406 2025-05-14

FLAME-1

Phase 2 Not yet recruiting

100 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05289908 2025-05-04

Intrathecal Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Completed

34 enrolled

CNS

Meningeal Carcinomatosis

NCT04192981 2025-04-17

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Phase 1 Active not recruiting

21 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT06901817 2025-03-30

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

Phase 2 Recruiting

97 enrolled

CNS

Meningeal Carcinomatosis

NCT05034497 2025-03-26

ReSPECT-LM

Phase 1 Active not recruiting

18 enrolled

CNS

Meningeal Carcinomatosis

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06812871 2025-02-06

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Recruiting

30 enrolled

CNS

Meningeal Carcinomatosis

NCT04233021 2025-02-03

ORBITAL

Phase 2 Completed

57 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT06766591 2025-01-09

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Phase NA Not yet recruiting

36 enrolled

CNS

Meningeal Carcinomatosis

NCT05146219 2024-12-30

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Phase 2 Completed

29 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT06728865 2024-12-11

Better Brain

Phase 2 Recruiting

70 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT00801216 2024-12-10

SCNSL1

Phase 2 Completed

40 enrolled 11 charts

CNSLymphoid

Lymphoma, B-Cell, Meningeal Carcinomatosis

NCT02948751 2024-06-06

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

Completed

14 enrolled 7 charts

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Phase 2 Not yet recruiting

112 enrolled

CNS

Meningeal Carcinomatosis

Clinical Trials

Exo-LCR

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Concurrent Azeliragon With Craniospinal Irradiation

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

HIT

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

CA2024-LM-001

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

DEBBRAH

LMD

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

FLAME-1

Intrathecal Pemetrexed for Leptomeningeal Metastasis

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

ReSPECT-LM

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

ORBITAL

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Better Brain

SCNSL1

Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI